ArticleBioactive materials2022
A ROS-responsive, self-immolative and self-reporting hydrogen sulfide donor with multiple biological activities for the treatment of myocardial infarction.
Article in Bioactive materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Inorganic, Synthetic, Natural, and Innovative Hybrid Hydrogen Sulfide Donors and Inhibitors of Its Biosynthesis in the Treatment of Central and Peripheral Nervous System Injuries: A Systematic Analytical Review.International journal of molecular sciences · 2025Pooled it
- Peptide-functionalized membrane camouflage for endogenous HNature communications · 2026Article
- Key Steps in Murine Cardiac Engineering Validation: How Does It Affect the Efficiency of Cardiac Devices?BioMed research international · 2026Review
- Impaired Diabetic Myocutaneous Wound Revascularization Is Associated With Reduced Transdermal HThe Journal of surgical research · 2025Article
- The therapeutic potential of hydrogen sulfide and its donors, a new discovery in vascular diseases.Journal of cardiovascular pharmacology · 2025Article
- Recent progress in ROS-responsive biomaterials for the diagnosis and treatment of cardiovascular diseases.Theranostics · 2025Review
- H2S inhibits high glucose-induced osteoblast injury by inhibiting ferroptosis in diabetic osteoporosis in vitro.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Recent advances in mitochondria-targeting theranostic agents.Exploration (Beijing, China) · 2024Review
- Hydrogen Sulfide can Scavenge Free Radicals to Improve Spinal Cord Injury by Inhibiting the p38MAPK/mTOR/NF-κB Signaling Pathway.Neuromolecular medicine · 2024Review
- Fluorescent small molecule donors.Chemical Society reviews · 2024Review
- An Expanded Palette of Fluorescent COS/HAngewandte Chemie (International ed. in English) · 2024Article
- Nanomotor-based HBioactive materials · 2024Article
- Reactive oxygen species (ROS)-responsive biomaterials for treating myocardial ischemia-reperfusion injury.Frontiers in bioengineering and biotechnology · 2024Review
- Harnessing the Therapeutic Potential of Ginsenoside Rd for Activating SIRT6 in Treating a Mouse Model of Nonalcoholic Fatty Liver Disease.ACS omega · 2023Article
- Nanomedicine-Based Therapeutics for Myocardial Ischemic/Reperfusion Injury.Advanced healthcare materials · 2023Review
- HBioactive materials · 2023Article
- CuNanoscale advances · 2023Article
- HAntioxidants (Basel, Switzerland) · 2023Review
- Role of hydrogen sulphide in physiological and pathological angiogenesis.Cell proliferation · 2023Review
- Macrophage Heterogeneity and Its Impact on Myocardial Ischemia-Reperfusion Injury: An Integrative Review.Journal of inflammation research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI), as one of the leading causes of global death, urgently needs effective therapies. Recently, hydrogen sulfide (H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.